NeuroOne Medical Technologies Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from NeuroOne Medical Technologies Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 94% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 93% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Sep 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-45.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 70% of Healthcare companies in United States.
Cash Locked Ratio
$27For every $100 of sales, $27 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $111 from others' credit three years earlier.
More money tied up than 58% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$72Sales grew 5,215% in 3 years; of every extra $100 of sales, $72 became extra profit.
Higher than 75% of Healthcare companies in United States.
Asset Productivity Ratio
+5215% / -16%In 3 years sales changed by +5215% while total assets changed by -16%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-22.9×Operating cash was negative last year, while some debt falls due within a year.
Lower than 58% of Healthcare companies in United States.
Cash Cushion Ratio
+71%Cash, after subtracting all debt, equals 71% of its market value (net cash).
Higher than 83% of Healthcare companies in United States.
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 93% of Healthcare companies in United States.
Tangible Net Worth Ratio
99%Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 94% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
NeuroOne Medical Technologies Corporation made a loss over the last year. NeuroOne Medical Technologies Corporation owes $0.39 for every $1 it owns. NeuroOne Medical Technologies Corporation made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Sep 2025.
P/E ratio
LossNeuroOne Medical Technologies Corporation made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.22The share price is 2.22 times NeuroOne Medical Technologies Corporation's book value per share, lower than 54% of Healthcare companies in United States.
Market cap
$8 MThe total market value of all of NeuroOne Medical Technologies Corporation's shares at today's price (share price × number of shares), smaller than 89% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$4 MWhat NeuroOne Medical Technologies Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.41Net worth divided by the number of shares. The share price of $0.92 is 2.2 times this, which is the P/B above.
Return on equity (ROE)
-124.7%NeuroOne Medical Technologies Corporation lost 124.7% of its shareholders' money over the last year, lower than 77% of Healthcare companies in United States.
Owes vs Owns
0.39×NeuroOne Medical Technologies Corporation owes $0.39 for every $1 it owns (low), lower than 52% of Healthcare companies in United States.
Dividend yield
NoneNeuroOne Medical Technologies Corporation does not currently pay a dividend.
Revenue growth
+163%Revenue rose 163% in the year to Sep 2025, and grew 276% a year on average over 3 years.
Profit growth
LossNeuroOne Medical Technologies Corporation made a loss in each of the last two years.
Profit margin
-39.6%NeuroOne Medical Technologies Corporation lost $40 for every $100 of revenue.
Interest cover
Not coveredNeuroOne Medical Technologies Corporation's operating profit did not cover its interest costs in the year to Sep 2025.
Cash vs debt
Net cashNeuroOne Medical Technologies Corporation held $6 M more cash than debt (net cash) at Sep 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For NeuroOne Medical Technologies Corporation: $8 M ÷ $4 M (30 Jun 2026) = 2.2.
What is NeuroOne Medical Technologies Corporation's return on equity?
NeuroOne Medical Technologies Corporation lost 124.7% of its shareholders' money over the last year, lower than 77% of Healthcare companies in United States.
How much does NeuroOne Medical Technologies Corporation owe compared with what it owns?
NeuroOne Medical Technologies Corporation owes $0.39 for every $1 it owns (low), lower than 52% of Healthcare companies in United States.
Does NeuroOne Medical Technologies Corporation pay a dividend?
No. NeuroOne Medical Technologies Corporation does not currently pay a dividend.
Is NeuroOne Medical Technologies Corporation's revenue growing?
Revenue rose 163% in the year to Sep 2025, and grew 276% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.